Search results for "INHIBITORS"

showing 10 items of 2336 documents

Neuroinflammatory and behavioral susceptibility profile of mice exposed to social stress towards cocaine effects.

2021

Using the social defeat (SD) model, numerous studies have shown that stressed mice display an enhanced response to the motivational effects of cocaine in the self-administration (SA) and conditioned-place preference (CPP) paradigms. However, not all subjects exposed to stress express its harmful effects. Some are particularly susceptible to the deleterious effects of repeated SD, while resilient mice successfully cope with stressful experiences and display adjusted psychological functioning after stress. Vulnerability to develop stress-related disorders, such as depression, has been linked to coping strategies and more recently to individual differences in the immune system. However, no stu…

medicine.medical_treatmentHippocampusStriatumHippocampusSocial defeat03 medical and health sciences0302 clinical medicineImmune systemNeuroinflammationCocaineDopamine Uptake InhibitorsSocial defeatConditioning PsychologicalMedicineAnimalsCX3CL1CytokineBiological PsychiatryNeuroinflammationPharmacologySocial stressResilienceBehavior Animalbusiness.industryChemokine CX3CL1Corpus Striatum030227 psychiatryPsicobiologiaCytokineChemokineSusceptibilityImmunologyCytokinesbusinessStress PsychologicalProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Nitric oxide and sensory afferent neurones modulate the protective effects of low-dose endotoxin on rat gastric mucosal damage

1995

Pretreatment (1 h) with low doses (5-40 micrograms/kg i.p.) of Escherichia coli endotoxin dose dependently reduced the gastric mucosal damage induced by a 10 min challenge with 1 ml ethanol (50% and 100%) in conscious rats. Treatment with the nitric oxide synthesis inhibitor, NG-nitro-L-arginine methyl ester (L-NAME, 5 and 10 mg/kg i.p.), significantly inhibited the protective effects of endotoxin (40 micrograms/kg i.p.). The actions of L-NAME were reversed by the prior administration of L-arginine (100 mg/kg i.p.). The protective effects of endotoxin were not influenced by pretreatment with dexamethasone (5 mg/kg s.c. twice) or indomethacin (5 mg/kg s.c.). However, ablation of sensory affe…

medicine.medical_treatmentIndomethacinPharmacologyArginineDexamethasoneNitric oxideRats Sprague-Dawleychemistry.chemical_compoundEscherichia colimedicineAnimalsNeurons AfferentEnzyme InhibitorsAntidoteDexamethasonePharmacologyAnalysis of VarianceEthanolEthanolSensory neuronRatsEndotoxinsNG-Nitroarginine Methyl Estermedicine.anatomical_structureMechanism of actionchemistryGastric MucosaCapsaicinAnesthesiaToxicityFemaleCapsaicinNitric Oxide Synthasemedicine.symptomInjections Intraperitonealmedicine.drugEuropean Journal of Pharmacology
researchProduct

Group 1 ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes

2018

The following article: Jung, R.E., Al-Nawas, B., Araujo, M., Avila-Ortiz, G., Barter, S., Brodala, N., ... Windisch, P. (2018). Group 1 ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes. Clinical Oral Implants Research, 29(S16), 69-77, can be accessed at https://doi.org/10.1111/clr.13342. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Objectives: The aim of Working Group 1 was to address the influence of different local (implant length, diameter, and design) and systemic (medications) factors on clinical, radiographic, and patient‐re…

medicine.medical_treatmentOsteoporosisbiological complicationsDentistryOsteoporosis/complicationsmeta-analysilaw.inventionProton Pump Inhibitors/adverse effects0302 clinical medicineRandomized controlled triallawRadiography DentalDental Restoration FailureDental implanthumans610 Medicine & healthclinical decision-makingdental implantDiphosphonatesnarrow diameter3504 Oral SurgeryJaw Edentulous Partially05 social sciencesDental Implantation EndosseousImplant failuredrugsmall dental implantVDP::Medisinske Fag: 700::Klinisk odontologiske fag: 830failureclinical decision‐makingDiphosphonates/adverse effectsMeta-analysisrandomized controlled trials/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingepidemiologymedicationOral SurgerySelective Serotonin Reuptake InhibitorsConsensusreview610 Medicine & healthsurvival03 medical and health sciences10068 Clinic of Reconstructive DentistrySDG 3 - Good Health and Well-beingdental implants0502 economics and businessmedicineshort dental implantsHumansbiological complicationPatient Reported Outcome MeasureshumanSurvival ratesmall dental implantsDental Implantsbusiness.industryJaw Edentulous Partially/rehabilitationshort dental implantProton Pump Inhibitors030206 dentistrymedicine.diseaseendosseous implantSurvival AnalysisVDP::Medical disciplines: 700::Clinical dentistry disciplines: 830Dental Prosthesis Designmeta‐analysisRelative riskrandomized controlled trialOsteoporosis050211 marketingImplantSerotonin Uptake Inhibitors/adverse effectsbusinessosteotomySystematic Reviews as Topic
researchProduct

Salts of 5-amino-2-sulfonamide-1,3,4-thiadiazole, a structural and analog of acetazolamide, show interesting carbonic anhydrase inhibitory properties…

2015

Three salts of 5-amino-2-sulfonamide-1,3,4-thiadiazole (Hats) were prepared and characterized by physico-chemical methods. The p-toluensulfonate, the methylsulfonate, and the chlorhydrate monohydrate salts of Hats were evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors (CAIs) and as anticonvulsants and diuretics, since many CAIs are clinically used as pharmacological agents. The three Hats salts exhibited diuretic and anticonvulsant activities with little neurotoxicity. The human (h) isoforms hCA I, II, IV, VII, IX, and XII were inhibited in their micromolar range by these salts, whereas pathogenic beta and gamma CAs showed similar, weak inhibitory profiles.

medicine.medical_treatmentPharmacology01 natural sciencesIsozymeThiadiazolesCarbonic anhydraseThiadiazolesDrug DiscoverymedicineHumansCarbonic Anhydrase InhibitorsDiureticsPharmacologySulfonamidesbiology010405 organic chemistryChemistrySulfonamide (medicine)NeurotoxicityGeneral Medicinemedicine.disease0104 chemical sciencesAcetazolamideIsoenzymes010404 medicinal & biomolecular chemistryAnticonvulsantbiology.proteinAnticonvulsantsDiureticAcetazolamidemedicine.drug
researchProduct

A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase

2002

Abstract In a previous study, we reported a new pyrroloquinazoline derivative, 3-(4′-acetoxy-3′,5′-dimethoxy)benzylidene-1,2-dihydropyrrolo[2,1- b ]quinazoline-9-one (PQ), which inhibited human purified 5-lipoxygenase activity and prostaglandin E 2 release in lipopolysaccharide-stimulated RAW 264.7 cells. In the present work, we show that PQ inhibits cyclo-oxygenase-2 activity in intact cell assays (human monocytes) and purified enzyme preparations (ovine isoenzymes) without affecting cyclo-oxygenase-1 activity. This behaviour was confirmed in vivo by using the zymosan-injected mouse air pouch model, where PQ caused a marked reduction in cell migration and leukotriene B 4 levels at 4 h, as …

medicine.medical_treatmentPharmacologyMonocytesMicechemistry.chemical_compoundIn vivomedicineAnimalsEdemaHumansCyclooxygenase InhibitorsPyrrolesLipoxygenase InhibitorsEnzyme InhibitorsProstaglandin E2Pain MeasurementPharmacologyAnalgesicsArachidonate 5-LipoxygenaseSheepCyclooxygenase 2 InhibitorsDose-Response Relationship DrugbiologyChemistryAnti-Inflammatory Agents Non-SteroidalZymosanMembrane ProteinsBiological activityIsoenzymesBiochemistryMechanism of actionCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme inhibitorArachidonate 5-lipoxygenaseQuinazolinesQuinolinesbiology.proteinFemalemedicine.symptomProstaglandin Emedicine.drug
researchProduct

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment

2020

The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified because of its key role in the regulation of glycogen synthesis. However, it is now well-established that GSK-3 performs critical functions in many cellular processes, such as apoptosis, tumor growth, cell invasion, and metastasis. Aberrant GSK-3 activity has been associated with many human diseases, including cancer, highlighting its potential therapeutic relevance as a target for anticancer therapy. Recently, newly emerging data have demonstrated the pivotal role of GSK-3 in the anticancer immune response. In the last few years, many GSK-3 inhibitors have been developed, and some are currently being te…

medicine.medical_treatmentT cellsReviewmacromolecular substancesNK cellsMetastasisGlycogen Synthase Kinase 3MiceImmune systemCancer immunotherapyGSK-3NeoplasmsPD-1medicineAnimalsHumanscancerGlycogen synthaselcsh:QH301-705.5GSK-3biologyKinasebusiness.industryCancerGeneral MedicineImmunotherapymedicine.diseasesmall molecule inhibitorsDisease Models Animalglycogen synthase kinase-3 (GSK-3)lcsh:Biology (General)Cancer researchbiology.proteinCTLA-4immunotherapybusiness
researchProduct

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guideline…

2010

Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn's and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these reasons the Italian Society of Gastroenterology and the Italian Group for the study of Inflammatory Bowel Disease have decided to elaborate the Italian guidelines on the use of biologics in Inflammatory…

methods Tumor Necrosis Factor-alphaAnti-Inflammatory AgentsUlcerativeDiseaseGUIDELINESHumanized Antibodieetiology Pregnancy Pregnancy ComplicationGastroenterologyInflammatory bowel diseaseetiology Opportunistic InfectionCrohn DiseasePregnancyNeoplasmsMonoclonaldrug therapy Remission Inductionantagonists /&/ inhibitorsSettore MED/12 - GastroenterologiaRemission InductionGastroenterologyAntibodies MonoclonalUlcerative colitisAnti-Inflammatory AgentItalyadverse effects/therapeutic use Intestinal FistulaTumor necrosis factor alphaFemaleImmunosuppressive Agentsmedicine.drugbiological drugsmedicine.medical_specialtyIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedAutoimmune Diseasesadverse effects/therapeutic use Autoimmune DiseaseInternal medicinemedicineAdalimumabIntestinal FistulaHumansColitisdiagnosis/drug therapy/surgery Italy Neoplasmadverse effects/therapeutic use AntibodieHepatologydrug therapy Female Humans Immunosuppressive Agentbusiness.industryTumor Necrosis Factor-alphaAdalimumabCancermedicine.diseaseInfliximabInfliximabdigestive system diseasesdrug therapy Crohn Diseaseetiology ColitiPregnancy ComplicationsColitis Ulcerativebusiness
researchProduct

Case-specific performance of MM-PBSA, MM-GBSA, and SIE in virtual screening.

2015

In drug discovery the reliable prediction of binding free energies is of crucial importance. Methods that combine molecular mechanics force fields with continuum solvent models have become popular because of their high accuracy and relatively good computational efficiency. In this research we studied the performance of molecular mechanics generalized Born surface area (MM-GBSA), molecular mechanics Poisson-Boltzmann surface area (MM-PBSA), and solvated interaction energy (SIE) both in their virtual screening efficiency and their ability to predict experimentally determined binding affinities for five different protein targets. The protein-ligand complexes were derived with two different app…

molecular mechanics generalized Born surface areaPhosphodiesterase InhibitorsMolecular Dynamics Simulationta3111Molecular mechanicsMolecular Docking Simulationbeta-LactamasesMolecular dynamicssolvated interaction energyBacterial ProteinsComputational chemistryAldehyde ReductaseDrug DiscoveryMaterials ChemistryHumansHSP90 Heat-Shock ProteinsPhysical and Theoretical ChemistryBeta-Lactamase InhibitorsSpectroscopymolecular mechanics Poisson-Boltzmann surface areaMM-GBSAVirtual screeningBinding SitesChemistryPhosphoric Diester Hydrolasesta1182Hydrogen BondingInteraction energyvirtual screeningComputer Graphics and Computer-Aided DesignMolecular Docking SimulationMM-PBSAModels ChemicalROC CurveSolvent modelsDocking (molecular)Area Under CurveBiological systemReceptors Progesteronebeta-Lactamase InhibitorsHydrophobic and Hydrophilic InteractionsProtein BindingJournal of molecular graphicsmodelling
researchProduct

Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.

2022

Abstract Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentEffectivenessYoung AdultInternal medicineAdalimumabMedicineHumansAdverse effectskin and connective tissue diseasesColectomyColectomyAgedRetrospective StudiesReal-world evidenceHepatologybusiness.industryGastroenterologyEffectiveneAdalimumabRetrospective cohort studyInduction ChemotherapyMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuationClinical PracticeTreatment OutcomeUlcerative colitisItalyAdalimumab; Effectiveness; Real-world evidence; Safety; Ulcerative colitisConcomitantColitis UlcerativeFemaleTumor Necrosis Factor InhibitorsSafetybusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

2010

Chondrosarcomas are resistant to conventional chemo- and radiotherapy. A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis. We therefore investigated the effect of selective COX-2 inhibition on chondrosarcoma growth. COX-2 expression was studied in central- and peripheral cartilaginous tumours. The effect of COX-2 inhibition was assessed in four high-grade chondrosarcoma cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin E-2 (PGE(2)) ELISA) and cell viability were measured. The (prophylactic) effect of celecoxib o…

musculoskeletal diseasesMaleCancer ResearchPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentChondrosarcomaDrug Evaluation PreclinicalMice NudeAntineoplastic AgentsBone NeoplasmsMiceIn vivomedicineTumor Cells CulturedAnimalsHumansViability assaySulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryCartilagemedicine.diseaseXenograft Model Antitumor AssaysRadiation therapyDisease Models Animalmedicine.anatomical_structureOncologyBone tumours Chondrosarcoma COX-2 inhibition Therapy Xenograft familial adenomatous polyposis cell-line cyclooxygenase-2 inhibitor trial tumors establishment emphasis origin boneCell cultureCelecoxibCyclooxygenase 2CelecoxibPyrazolesChondrosarcomabusinessmedicine.drugProstaglandin E
researchProduct